Nurix Therapeutics, Inc. (NASDAQ:NRIX) Insider Gwenn Hansen Sells 2,007 Shares

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Gwenn Hansen sold 2,007 shares of the firm’s stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $12.04, for a total value of $24,164.28. Following the transaction, the insider now owns 39,601 shares in the company, valued at approximately $476,796.04. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Nurix Therapeutics Stock Up 8.8 %

NASDAQ NRIX opened at $13.08 on Thursday. Nurix Therapeutics, Inc. has a 52-week low of $4.22 and a 52-week high of $18.12. The business’s 50-day moving average price is $13.76 and its 200 day moving average price is $9.86. The firm has a market cap of $642.88 million, a P/E ratio of -4.92 and a beta of 2.06.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings results on Thursday, February 15th. The company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.26). The firm had revenue of $15.16 million for the quarter, compared to analyst estimates of $30.66 million. Nurix Therapeutics had a negative return on equity of 67.08% and a negative net margin of 178.93%. As a group, analysts anticipate that Nurix Therapeutics, Inc. will post -3.15 earnings per share for the current year.

Hedge Funds Weigh In On Nurix Therapeutics

Large investors have recently modified their holdings of the business. SG Americas Securities LLC purchased a new stake in shares of Nurix Therapeutics during the 3rd quarter worth $162,000. Raymond James & Associates lifted its stake in shares of Nurix Therapeutics by 6.0% in the third quarter. Raymond James & Associates now owns 97,988 shares of the company’s stock valued at $770,000 after purchasing an additional 5,547 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of Nurix Therapeutics by 2.9% in the third quarter. Bank of New York Mellon Corp now owns 170,286 shares of the company’s stock valued at $1,338,000 after purchasing an additional 4,816 shares during the period. Principal Financial Group Inc. boosted its holdings in Nurix Therapeutics by 14.8% during the third quarter. Principal Financial Group Inc. now owns 15,531 shares of the company’s stock worth $122,000 after buying an additional 2,002 shares in the last quarter. Finally, Los Angeles Capital Management LLC grew its position in Nurix Therapeutics by 15.6% during the third quarter. Los Angeles Capital Management LLC now owns 125,839 shares of the company’s stock worth $989,000 after buying an additional 16,989 shares during the period.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on NRIX shares. Wells Fargo & Company decreased their price objective on Nurix Therapeutics from $23.00 to $20.00 and set an “overweight” rating for the company in a report on Friday, February 16th. HC Wainwright decreased their price target on shares of Nurix Therapeutics from $35.00 to $19.00 and set a “buy” rating for the company in a research note on Tuesday, February 20th. Morgan Stanley lifted their price objective on shares of Nurix Therapeutics from $9.00 to $10.00 and gave the company an “equal weight” rating in a research note on Monday, February 26th. Robert W. Baird upped their target price on shares of Nurix Therapeutics from $24.00 to $25.00 and gave the company an “outperform” rating in a report on Thursday, April 11th. Finally, Royal Bank of Canada raised their price target on Nurix Therapeutics from $22.00 to $23.00 and gave the stock an “outperform” rating in a report on Thursday, April 11th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, Nurix Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $21.33.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.